Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicaid Drug Formulary Ideas Floated, But US Manufacturers Are Skeptical

Executive Summary

Medicaid formularies capable of excluding drugs to drive better rebates could replace the existing drug rebate program, lobbyists suggest, but US manufacturers worry that lawmakers will be leery of losing statutory-based rebates.

You may also be interested in...



Medicaid Reform: Trump Administration Pursuing Rebates Over 100%

States might also be able to test closed formularies in Medicaid as Trump Administration seeks stronger disincentives for price increases.

Closed Formularies in Medicaid? Massachusetts Could Set Precedent

State requests waiver from Centers for Medicare and Medicaid Services to use closed formulary in its Medicaid program as a way to lower prescription drug costs.

Amgen's Ofman On Value-Based Contracts And Reimbursement Challenges

Amgen has negotiated 75 value-based contracts – agreements that SVP Josh Ofman sees as one area where biopharma and payer views are aligned. However, tension between the two sides remains high in pricing and reimbursement negotiations when it comes to rebates and other issues.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS120132

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel